Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system

AIDS

Volumn 27, Issue 13, 2013, Pages 2031-2040

  Hecht, Markus ^a   Harrer, Thomas ^a   Büttner, Maike ^a   Schwegler, Manuela ^a   Erber, Sonja ^a   Fietkau, Rainer ^a   Distel, Luitpold V ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cancer; Cannabinoid; Chemotherapy; Efavirenz; HIV; Nonnucleoside reverse transcriptase inhibitor

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANNEXIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR GPR55; EFAVIRENZ; EMTRICITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; RIMONABANT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER TISSUE; CONTROLLED STUDY; CYTOTOXICITY; FIBROBLAST CULTURE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING;

ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; BENZOXAZINES; BLOTTING, WESTERN; CELL LINE, TUMOR; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CANNABINOID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884499892     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283625444     Document Type: Article

References (63)

1. Bonnet F, Burty C, Lewden C, Costagliola D,May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-639.
2. Firnhaber C, Westreich D, Schulze D, Williams S, Siminya M, Michelow P, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc 2012; 15:1-6.
3. Memiah P, Mbuthia W, Kiiru G, Agbor S, Odhiambo F, Ojoo S, Biadgilign S. Prevalence and risk factors associated with precancerous cervical cancer lesions among HIV-infected women in resource-limited settings. AIDS Res Treat 2012; 2012: 953743.
4. van der Snoek EM, van der Ende ME, den Hollander JC, Schutten M, Neumann HA, van Doornum GJ. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis 2012; 39:495-500.
5. Adler DH, Kakinami L, Modisenyane T, Tshabangu N, Mohapi L, De Bruyn G, et al. Increased regression and decreased incidence of HPV-related cervical lesions among HIV-infected women on HAART. AIDS 2012; 26:1645-1652.
6. Omar T, Schwartz S, Hanrahan C, Modisenyane T, Tshabangu N, Golub JE, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS 2011; 25:87-94.
7. Mangiacasale R, Pittoggi C, Sciamanna I, Careddu A, Mattei E, Lorenzini R, et al. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 2003; 22: 2750-2761.
8. Gottesman L. Sustiva may cause false positive on marijuana test. World 1999; 96:7.
9. la Porte CJ, Droste JA, Burger DM. False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin. Ther Drug Monit 2006; 28:286.
10. Roder CS, Heinrich T, Gehrig AK, Mikus G. Misleading results of screening for illicit drugs during efavirenz treatment. AIDS 2007; 21:1390-1391.
11. Rossi S, Yaksh T, Bentley H, van den Brande G, Grant I, Ellis R. Characterization of interference with 6 commercial delta9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine. Clin Chem 2006; 52:896-897.
12. Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett 2009; 285:6-12.
13. Flygare J, Sander B. The endocannabinoid system in cancerpotential therapeutic target? Semin Cancer Biol 2008; 18:176-189.
14. Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 2009; 60:107-116.
15. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008; 68:339-342.
16. Brown I, Cascio MG, Rotondo D, Pertwee RG, Heys SD, Wahle KW. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog Lipid Res 2013; 52:80-109.
17. Calvaruso G, Pellerito O, Notaro A, Giuliano M. Cannabinoidassociated cell death mechanisms in tumor models (review). Int J Oncol 2012; 41:407-413.
18. Ellert-Miklaszewska A, Ciechomska I, Kaminska B. Cannabinoid signaling in glioma cells. Adv Exp Med Biol 2013; 986: 209-220.
19. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids and cancer. Cancer Metastasis Rev 2011; 30:599-612.
20. Lubgan D, Nkenke E, Fietkau R, Distel L. Vergleichende Untersuchung zur Strahlenempfindlichkeit von Plattenepithelkarzinomzellen und Fibroblasten der Mundhöhle [Comparative investigation of radiosensitivity of squamous cell carcinoma cells and fibroblasts of the oral cavity]. Strahlenther Onkol 2009; 185:159.
21. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-1420.
22. Endt H, Sprung CN, Keller U, Gaipl U, Fietkau R, Distel LV. Detailed analysis of DNA repair and senescence marker kinetics over the life span of a human fibroblast cell line. J Gerontol A Biol Sci Med Sci 2011; 66:367-375.
23. Wittlinger M, Grabenbauer GG, Sprung CN, Sauer R, Distel LV. Time and dose-dependent activation of p53 serine 15 phosphorylation among cell lines with different radiation sensitivity. Int J Radiat Biol 2007; 83:245-257.
24. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumorinfiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006; 12:3355-3360.
25. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009; 9:65.
26. Bedner E, Li X, Gorczyca W, Melamed MR, Darzynkiewicz Z. Analysis of apoptosis by laser scanning cytometry. Cytometry 1999; 35:181-195.
27. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-279.
28. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010; 17:1360-1381.
29. Hsieh C, Brown S, Derleth C, Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 1999; 73:493-501.
30. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 2004; 279:36013-36021.
31. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 2007; 152:825-831.
32. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152:1092-1101.
33. Howlett AC, Blume LC, Dalton GD. CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem 2010; 17:1382-1393.
34. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 2010; 44:75-85.
35. Landriscina M, Fabiano A, Altamura S, Bagala C, Piscazzi A, Cassano A, et al. Reverse transcriptase inhibitors downregulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 2005; 90: 5663-5671.
36. Pittoggi C, Martis G, Mastrangeli G, Mastrangeli B, Spadafora C. In vitro evidence for a new therapeutic approach in renal cell carcinoma. Int Braz J Urol 2008; 34:492-502.
37. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005; 24:3923-3931.
38. Sinibaldi-Vallebona P, Lavia P, Garaci E, Spadafora C. A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy. Genes Chromosomes Cancer 2006; 45:1-10.
39. Ferguson TA, Choi J,GreenDR. Armed response: how dying cells influence T-cell functions. Immunol Rev 2011; 241:77-88.
40. Fumaz CR, Tuldra A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002; 29:244-253.
41. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007; 4:1744-1769.
42. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4:62-66.
43. Grimaldi C, Capasso A. The endocannabinoid system in the cancer therapy: an overview. CurrMed Chem 2011; 18:1575-1583.
44. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009; 45:174-182.
45. Gustafsson SB, Palmqvist R, Henriksson ML, Dahlin AM, Edin S, Jacobsson SO, et al. High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One 2009; 6:e23003.
46. Gallotta D, Nigro P, Cotugno R, Gazzerro P, Bifulco M, Belisario MA. Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. Biochem Pharmacol 2010; 80:370-380.
47. Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, et al. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer 2009; 125:996-1003.
48. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C, Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 2006; 70:1298-1306.
49. Landriscina M, Altamura SA, Roca L, Gigante M, Piscazzi A, Cavalcanti E, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer 2008; 122: 2842-2850.
50. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011; 2011:978312.
51. Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011; 2011:603925.
52. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006; 281:39480-39491.
53. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
54. Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A, Pascual-Carrasco R, Rodriguez-Diez M, Lucero-Munoz MJ. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr 2005; 39:551-556.
55. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19:1481-1486.
56. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-541.
57. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137:413-431.
58. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-1334.
59. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-665.
60. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009; 23:1701-1706.
61. Amengual JE, Zhang X, Ibrahim S, Gardner LB. Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone. Blood 2008; 112:4359-4360.
62. Girard T, Luquet-Besson I, Baran-Marszak F, Raphael M, Boue F. HIV + MALT lymphoma remission induced by highly active antiretroviral therapy alone. Eur J Haematol 2005; 74:70-72.
63. Kato T, Ieki R, Saito E, Ota T, Yuasa K, Iguchi M, et al. A longterm survival case of small cell lung cancer in an HIV-infected patient. Jpn J Clin Oncol 2005; 35:349-352.